146 related articles for article (PubMed ID: 20619309)
1. Assessment of undesirable events in cosmetic market surveillance: background, description and use of a causality assessment method in cosmetovigilance.
Bons B; Audebert F; Bitaudeau C; Cachin N; Colson L; Farr C; Fix LA; Gilmour N; Gorni R; Griffiths M; Harris B; Holle V; Kirk S; Meredith E; Pari C; Poinsot P; Renner G;
Regul Toxicol Pharmacol; 2010 Dec; 58(3):349-53. PubMed ID: 20619309
[No Abstract] [Full Text] [Related]
2. Causality methods in cosmetovigilance: comparison of Colipa and PLM versus global introspection.
Zweers PG; Gilmour NJ; Hepburn PA; Gerritsen RF; van Puijenbroek EP
Regul Toxicol Pharmacol; 2012 Aug; 63(3):409-17. PubMed ID: 22609380
[TBL] [Abstract][Full Text] [Related]
3. Cosmetovigilance: definition, regulation and use "in practice".
Vigan M; Castelain F
Eur J Dermatol; 2014; 24(6):643-9. PubMed ID: 25672787
[TBL] [Abstract][Full Text] [Related]
4. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
Lodén M; Ungerth L; Serup J
Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
[TBL] [Abstract][Full Text] [Related]
5. [Cosmetovigilance: a French pharmacovigilance system for cosmetics developed by the French health products safety agency. A proposal for the future].
Tissier MH; Lepagnol F
Therapie; 2002; 57(3):273-82. PubMed ID: 12422542
[TBL] [Abstract][Full Text] [Related]
6. [Sanitary control of cosmetics].
Bonini M; Pellino P; Pilla M
Ig Sanita Pubbl; 2005; 61(3):271-84. PubMed ID: 17206194
[TBL] [Abstract][Full Text] [Related]
7. Cosmetovigilance: the 'beautiful' risk.
Moretti U; Velo G
Drug Saf; 2008; 31(5):437-9. PubMed ID: 18422387
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring cosmetic product safety].
Vigan M
Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S55-8. PubMed ID: 17563716
[No Abstract] [Full Text] [Related]
9. FDA's response to food, dietary supplement, and cosmetic adverse events.
Bren L
FDA Consum; 2003; 37(4):12-3. PubMed ID: 12971342
[No Abstract] [Full Text] [Related]
10. EU and US clinical investigation adverse event reporting.
Crowley G
Med Device Technol; 2004 Jun; 15(5):30-2. PubMed ID: 15285486
[TBL] [Abstract][Full Text] [Related]
11. Safety assessment of cosmetic ingredients present in technical information files of finished products.
Rogiers V; Pauwels M
Curr Probl Dermatol; 2008; 36():94-114. PubMed ID: 18806455
[No Abstract] [Full Text] [Related]
12. Safety evaluation of cosmetics in the EU. Reality and challenges for the toxicologist.
Pauwels M; Rogiers V
Toxicol Lett; 2004 Jun; 151(1):7-17. PubMed ID: 15177635
[TBL] [Abstract][Full Text] [Related]
13. Understanding the adverse effects of cosmetics: a pilot project in cosmetovigilance.
Sautebin L
Drug Saf; 2008; 31(5):433-6. PubMed ID: 18422386
[TBL] [Abstract][Full Text] [Related]
14. Beyond the US submisson process.
Donawa M
Med Device Technol; 2004 Apr; 15(3):30-2. PubMed ID: 15255536
[TBL] [Abstract][Full Text] [Related]
15. The need for human data: the role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes.
Forbes AL
Regul Toxicol Pharmacol; 1996 Feb; 23(1 Pt 2):S20-1; discussion S31-7. PubMed ID: 8801611
[TBL] [Abstract][Full Text] [Related]
16. Post-marketing strategies for medicines.
Breckenridge A
Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
[No Abstract] [Full Text] [Related]
17. [Pharmacologic surveillance and safety evaluation of new drugs].
Reys LL
Acta Med Port; 1991; 4(3):141-6. PubMed ID: 1950664
[TBL] [Abstract][Full Text] [Related]
18. Safety assurance of cosmetics in Japan: current situation and future prospects.
Inomata S
J Oleo Sci; 2014; 63(1):1-6. PubMed ID: 24389794
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars approval process.
Zuñiga L; Calvo B
Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
[TBL] [Abstract][Full Text] [Related]
20. US and European postmarket clinical data requirements.
Donawa M
Med Device Technol; 2005 Mar; 16(2):19-21. PubMed ID: 15828495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
